Salvage radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer based on 18F-fluciclovine PET/CT guidance
OA Abiodun-Ojo, AB Jani, AA Akintayo… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Imaging with novel PET radiotracers has significantly influenced radiotherapy decision
making and radiation planning in patients with recurrent prostate cancer (PCa). The purpose …
making and radiation planning in patients with recurrent prostate cancer (PCa). The purpose …
Change in salvage radiotherapy management based on guidance with FACBC (fluciclovine) PET/CT in postprostatectomy recurrent prostate cancer
Purpose We explored the influence of FACBC (fluciclovine) PET/CT on the decision to offer
radiotherapy and radiotherapy treatment field recommendations in postprostatectomy …
radiotherapy and radiotherapy treatment field recommendations in postprostatectomy …
[HTML][HTML] Effect of 18F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial
AF Scarsbrook, D Bottomley, EJ Teoh… - International Journal of …, 2020 - Elsevier
Purpose Early and accurate localization of lesions in patients with biochemical recurrence
(BCR) of prostate cancer may guide salvage therapy decisions. The present study, 18 F …
(BCR) of prostate cancer may guide salvage therapy decisions. The present study, 18 F …
A prospective study of 18F-DCFPyL PSMA PET/CT restaging in recurrent prostate cancer following primary external beam radiotherapy or brachytherapy
Purpose Radio-recurrent prostate cancer is typically detected by a rising prostate-specific
antigen and may reflect local or distant disease. Positron emission tomography (PET) …
antigen and may reflect local or distant disease. Positron emission tomography (PET) …
18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre …
Background Molecular imaging is increasingly used to guide treatment decisions and
planning in prostate cancer. We aimed to evaluate the role of 18 F-fluciclovine-PET/CT in …
planning in prostate cancer. We aimed to evaluate the role of 18 F-fluciclovine-PET/CT in …
Impact of 18F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy
Purpose We aimed to evaluate the impact of 18 F-fluciclovine PET/CT imaging on failure-
free survival (FFS) post–salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence …
free survival (FFS) post–salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence …
18F-fluciclovine positron emission tomography in men with biochemical recurrence of prostate cancer after radical prostatectomy and planning to undergo salvage …
Purpose Conventional imaging rarely localizes the site (s) of prostate cancer recurrence in
patients undergoing evaluation for salvage radiation therapy (sRT) after radical …
patients undergoing evaluation for salvage radiation therapy (sRT) after radical …
Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer
JD Soyka, MA Muster, DT Schmid, B Seifert… - European journal of …, 2012 - Springer
Purpose To investigate the clinical value of 18 F-fluorocholine PET/CT (CH-PET/CT) in
treatment decisions in patients with recurrent prostate cancer (rPCA). Methods The study …
treatment decisions in patients with recurrent prostate cancer (rPCA). Methods The study …
The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial
Purpose: The prospective, multicenter LOCATE (18F Fluciclovine [FACBC] PET/CT in
Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of …
Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of …
Impact of 18F-fluciclovine PET/CT on clinical management of patients with recurrent prostate cancer: results from the phase 3 FALCON trial
E Teoh, D Bottomley, A Scarsbrook… - International Journal of …, 2017 - redjournal.org
Results Between December 2015 and February 2017, 85 evaluable patients (median age at
screening, 67.0 y; median post-BCR PSA, 0.63 ng/mL) were imaged. Fifty-six (65.9%) had …
screening, 67.0 y; median post-BCR PSA, 0.63 ng/mL) were imaged. Fifty-six (65.9%) had …
Related searches
- prostate cancer fluciclovine pet
- salvage radiotherapy fluciclovine pet
- salvage radiotherapy prostate cancer
- prostate cancer postprostatectomy patients
- imaging alone fluciclovine pet
- empire 1 fluciclovine pet
- prostate cancer biochemical recurrence
- prostate cancer clinical management
- open label fluciclovine pet
- salvage radiotherapy imaging alone
- prostate cancer imaging alone
- prostate cancer radical prostatectomy
- salvage radiotherapy empire 1
- salvage radiotherapy open label
- prostate cancer empire 1
- prostate cancer open label